S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

KYMR Kymera Therapeutics Inc

40.90

1.76 (4.50%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Kymera Therapeutics Charts.

Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Kymera Therapeutics Charts.

Kymera Therapeutics Inc News

Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Tuesday 26 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Thursday 31 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 31 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 31 October 2024 (2 months ago) • Edgar (US Regulatory)

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
Thursday 24 October 2024 (2 months ago) • GlobeNewswire Inc.

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Wednesday 23 October 2024 (2 months ago) • GlobeNewswire Inc.

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Wednesday 23 October 2024 (2 months ago) • GlobeNewswire Inc.

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Wednesday 9 October 2024 (2 months ago) • GlobeNewswire Inc.

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Wednesday 25 September 2024 (3 months ago) • GlobeNewswire Inc.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Wednesday 28 August 2024 (4 months ago) • GlobeNewswire Inc.

More Kymera Therapeutics Inc News Articles

Ci Emerging Markets Corp...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions